This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

NeoStem's Suzhou Erye Pharmaceutical Receives Two Awards At The Chempharm Brand Summit 2011

NEW YORK, April 26, 2011 /PRNewswire/ -- NeoStem, Inc. ("NeoStem" or the "Company") (NYSE Amex: NBS), an international biopharmaceutical company with operations in the U.S. and China, today announced that its majority owned Suzhou Erye Pharmaceutical Company Ltd. subsidiary ("Erye Pharmaceutical") received two awards at the Chempharm Brand Summit 2011 in China.

During the 4th Chempharm Brand Summit held in Chengdu city from April 21st - 23rd, 2011, select recipients in the pharmaceutical industry were recognized by industry leaders with awards to reward outstanding achievement in specific categories.  Erye Pharmaceutical was awarded "Top 10 Anti-Infection Drug Award" and "Top 100 Brand Names Award".  

Madame Jian Zhang, Erye Pharmaceutical's General Manager, commented, "We are honored to have received such awards at the Chempharm Brand Summit and believe that our business will expand as we continue to transition to our new manufacturing facility."

Erye expects to be fully transitioned to its new 53,000 square meter state-of-the-art manufacturing facility this year.  This facility was built to be compliant with State Food and Drug Administration (SFDA) regulations and the latest current Good Manufacturing Practices (cGMP) global standards.  Approval (SFDA – Certificate of Approval) of the lyophilized (freeze dried) powder for injection production line is expected shortly.  Two additional production line approvals at the new plant (the oral active pharmaceutical ingredient (API) line and the capsule line) are expected by year end.  Omeprazole for GERD was launched in 2010 and is currently being manufactured at the new plant.  Production of the sterile API cloxacillin sodium which was approved in 2010 is scheduled to be launched and in production at the new facility once the cGMP line receives final SFDA approval. Erye Pharmaceutical has an additional five products in its pipeline and Erye Pharmaceutical and NeoStem continue to look for opportunities to in-license or acquire new drug opportunities to enhance the long-term growth potential of this business by fully utilizing the expanded capacity at the new facility.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

DOW 17,983.75 -142.37 -0.79%
S&P 500 2,112.66 -8.13 -0.38%
NASDAQ 5,077.6670 -20.3090 -0.40%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs